BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 30312905)

  • 1. Hybrid inorganic (nonporous silica)/organic (alginate) core-shell platform for targeting a cisplatin-based Pt(IV) anticancer prodrug.
    Ravera M; Gabano E; Bonzani D; Zanellato I; Arrais A; Cantamessa S; Biggiogera M; Osella D
    J Inorg Biochem; 2018 Dec; 189():185-191. PubMed ID: 30312905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functionalized nonporous silica nanoparticles as carriers for Pt(iv) anticancer prodrugs.
    Ravera M; Gabano E; Zanellato I; Perin E; Arrais A; Osella D
    Dalton Trans; 2016 Nov; 45(43):17233-17240. PubMed ID: 27722707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional fluorescent nonporous silica nanoparticles as carriers for Pt(IV) anticancer prodrugs.
    Ravera M; Perin E; Gabano E; Zanellato I; Panzarasa G; Sparnacci K; Laus M; Osella D
    J Inorg Biochem; 2015 Oct; 151():132-42. PubMed ID: 26277416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human Serum Albumin Conjugated Nanoparticles for pH and Redox-Responsive Delivery of a Prodrug of Cisplatin.
    Shi H; Cheng Q; Yuan S; Ding X; Liu Y
    Chemistry; 2015 Nov; 21(46):16547-54. PubMed ID: 26405808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineering liposomal nanoparticles of cholesterol-tethered amphiphilic Pt(iv) prodrugs with prolonged circulation time in blood.
    Datta P; Bang S; Yue Z; Beach T; Stilgenbauer M; Wang H; Bowers DJ; Kurokawa M; Xiao H; Zheng YR
    Dalton Trans; 2020 Jun; 49(24):8107-8113. PubMed ID: 32490446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Near-infrared light-mediated photoactivation of a platinum antitumor prodrug and simultaneous cellular apoptosis imaging by upconversion-luminescent nanoparticles.
    Min Y; Li J; Liu F; Yeow EK; Xing B
    Angew Chem Int Ed Engl; 2014 Jan; 53(4):1012-6. PubMed ID: 24311528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient co-delivery of a Pt(IV) prodrug and a p53 activator to enhance the anticancer activity of cisplatin.
    Ma R; Wang Y; Yan L; Ma L; Wang Z; Chan HC; Chiu SK; Chen X; Zhu G
    Chem Commun (Camb); 2015 May; 51(37):7859-62. PubMed ID: 25854514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
    Tan MX; Wang ZF; Qin QP; Zou BQ; Liang H
    Dalton Trans; 2020 Feb; 49(5):1613-1619. PubMed ID: 31942585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dual-targeting hybrid platinum(IV) prodrug for enhancing efficacy.
    Xiao H; Yan L; Zhang Y; Qi R; Li W; Wang R; Liu S; Huang Y; Li Y; Jing X
    Chem Commun (Camb); 2012 Nov; 48(87):10730-2. PubMed ID: 23012698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coordination-driven self-assembly of a Pt(iv) prodrug-conjugated supramolecular hexagon.
    Yue Z; Wang H; Li Y; Qin Y; Xu L; Bowers DJ; Gangoda M; Li X; Yang HB; Zheng YR
    Chem Commun (Camb); 2018 Jan; 54(7):731-734. PubMed ID: 29303526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro evaluation of folic acid-conjugated redox-responsive mesoporous silica nanoparticles for the delivery of cisplatin.
    Alvarez-Berríos MP; Vivero-Escoto JL
    Int J Nanomedicine; 2016; 11():6251-6265. PubMed ID: 27920531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monochalcoplatin: An Actively Transported, Quickly Reducible, and Highly Potent Pt
    Ma L; Wang N; Ma R; Li C; Xu Z; Tse MK; Zhu G
    Angew Chem Int Ed Engl; 2018 Jul; 57(29):9098-9102. PubMed ID: 29806087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
    Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY
    Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Lee VEY; Lim ZC; Chew SL; Ang WH
    Inorg Chem; 2021 Feb; 60(3):1823-1831. PubMed ID: 33464875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A conveniently synthesized Pt (IV) conjugated alginate nanoparticle with ligand self-shielded property for targeting treatment of hepatic carcinoma.
    Wang X; Chang Z; Nie X; Li Y; Hu Z; Ma J; Wang W; Song T; Zhou P; Wang H; Yuan Z
    Nanomedicine; 2019 Jan; 15(1):153-163. PubMed ID: 30308299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platinum(iv) prodrugs with long lipid chains for drug delivery and overcoming cisplatin resistance.
    Chen Q; Yang Y; Lin X; Ma W; Chen G; Li W; Wang X; Yu Z
    Chem Commun (Camb); 2018 May; 54(42):5369-5372. PubMed ID: 29744485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitric oxide-releasing platinum(IV) prodrug efficiently inhibits proliferation and metastasis of cancer cells.
    Dai Y; Zhu Y; Cheng J; Shen J; Huang H; Liu M; Chen Z; Liu Y
    Chem Commun (Camb); 2020 Nov; 56(90):14051-14054. PubMed ID: 33103676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted iron nanoparticles with platinum-(IV) prodrugs and anti-EZH2 siRNA show great synergy in combating drug resistance in vitro and in vivo.
    Yu C; Ding B; Zhang X; Deng X; Deng K; Cheng Z; Xing B; Jin D; Ma P; Lin J
    Biomaterials; 2018 Feb; 155():112-123. PubMed ID: 29175080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Pt(IV) Prodrug Combining Chlorambucil and Cisplatin: a Dual-Acting Weapon for Targeting DNA in Cancer Cells.
    Montagner D; Tolan D; Andriollo E; Gandin V; Marzano C
    Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30486477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Self-controlled release of Oxaliplatin prodrug from d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) functionalized mesoporous silica nanoparticles for cancer therapy.
    Liang C; Wang H; Zhang M; Cheng W; Li Z; Nie J; Liu G; Lian D; Xie Z; Huang L; Zeng X
    J Colloid Interface Sci; 2018 Sep; 525():1-10. PubMed ID: 29679795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.